These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19337160)

  • 1. Role of iron in osteoporosis.
    Weinberg ED
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():81-5. PubMed ID: 19337160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for thalassemia patients with osteoporosis.
    Terpos E; Voskaridou E
    Ann N Y Acad Sci; 2010 Aug; 1202():237-43. PubMed ID: 20712799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ; Kartikasari AE; Georgiou NA
    Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases.
    Nielsen P; Engelhardt R; Duerken M; Janka GE; Fischer R
    Transfus Sci; 2000 Dec; 23(3):257-8. PubMed ID: 11099909
    [No Abstract]   [Full Text] [Related]  

  • 6. Thalassemia: cardiac iron and chelators.
    Gaur A
    Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED
    J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the understanding of iron metabolism and iron-related diseases.
    Hoffbrand AV
    Acta Haematol; 2009; 122(2-3):75-7. PubMed ID: 19907143
    [No Abstract]   [Full Text] [Related]  

  • 9. Gender differences in the prevalence and severity of bone disease in thalassaemia.
    Kyriakou A; Savva SC; Savvides I; Pangalou E; Ioannou YS; Christou S; Skordis N
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats.
    Kudo H; Suzuki S; Watanabe A; Kikuchi H; Sassa S; Sakamoto S
    Toxicology; 2008 Apr; 246(2-3):143-7. PubMed ID: 18289763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload in myelodysplastic syndromes.
    Chodirker L; Wells RA
    Expert Rev Hematol; 2009 Jun; 2(3):215-8. PubMed ID: 21082962
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron loading: a risk factor for osteoporosis.
    Weinberg ED
    Biometals; 2006 Dec; 19(6):633-5. PubMed ID: 16648989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA; Gama S; Gil M; Gano L
    Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy.
    Tolis G; Politis C; Kontopoulou I; Poulatzas N; Rigas G; Saridakis C; Athanasiou V; Mortoglou A; Malachtari S; Ling N
    Birth Defects Orig Artic Ser; 1987; 23(5A):449-52. PubMed ID: 3120817
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of iron overload on bone remodeling in thalassemia.
    Piriyakhuntorn P; Tantiworawit A; Phimphilai M; Shinlapawittayatorn K; Chattipakorn SC; Chattipakorn N
    Arch Osteoporos; 2020 Sep; 15(1):143. PubMed ID: 32929613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating iron overload.
    Camaschella C
    N Engl J Med; 2013 Jun; 368(24):2325-7. PubMed ID: 23758239
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiomyopathy and pericardial effusion in a 7 year-old boy with beta-thalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload.
    De Sanctis V; Govoni MR; Sprocati M; Marsella M; Conti E
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():181-4. PubMed ID: 19337175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral iron chelators: new opportunities and new dilemmas.
    Hershko C
    Haematologica; 2006 Oct; 91(10):1307-12. PubMed ID: 17018378
    [No Abstract]   [Full Text] [Related]  

  • 19. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferiprone is superior to deferasirox and desferrioxamine in cardiac iron overload.
    Manglani MV
    Indian Pediatr; 2012 Aug; 49(8):682. PubMed ID: 22962249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.